| Literature DB >> 14561090 |
Alejandra Trejo1, Humberto Arzeno, Michelle Browner, Sushmita Chanda, Soan Cheng, Daniel D Comer, Stacie A Dalrymple, Pete Dunten, JoAnn Lafargue, Brett Lovejoy, Jose Freire-Moar, Julie Lim, Joel Mcintosh, Jennifer Miller, Eva Papp, Deborah Reuter, Rick Roberts, Florentino Sanpablo, John Saunders, Kyung Song, Armando Villasenor, Stephen D Warren, Mary Welch, Paul Weller, Phyllis E Whiteley, Lu Zeng, David M Goldstein.
Abstract
Inhibition of the biosynthesis of proinflammatory cytokines such as tumor necrosis factor and interleukin-1 via p38 has been an approach toward the development of a disease modifying agent for the treatment of chronic inflammation and autoimmune diseases. The development of a new core structure of p38 inhibitors, 3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrolo[3,2-b] pyridine, is described. X-ray crystallographic data of the lead bound to the active site of p38 was used to guide the optimization of the series. Specific focus was placed on modulating the physical properties of the core while maintaining potent inhibition of p38. These efforts identified 42c as a potent inhibitor of p38, which also possessed the required physical properties worthy of advanced studies.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14561090 DOI: 10.1021/jm0301787
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446